Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide.

[1]  M. Humbert,et al.  Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. , 2010, European heart journal.

[2]  R. Califf,et al.  Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.

[3]  H. Ghofrani,et al.  Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension , 2008, Circulation.

[4]  Z. Jing,et al.  Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. , 2006, Journal of the American College of Cardiology.

[5]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[6]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[7]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[8]  D. Mccrory,et al.  Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .

[9]  O. Franklin,et al.  Adenosine infusion for the management of persistent pulmonary hypertension of the newborn* , 2004, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[10]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[11]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[12]  R. Tabrizchi,et al.  Pharmacology of adenosine receptors in the vasculature. , 2001, Pharmacology & therapeutics.

[13]  W. Seeger,et al.  A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[14]  R. Simms,et al.  Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). , 1999, Arthritis and rheumatism.

[15]  M. Humbert,et al.  Primary pulmonary hypertension associated with the use of fenfluramine derivatives. , 1998, Chest.

[16]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[17]  R. McIntyre,et al.  Adenosine for refractory pulmonary hypertension. , 1996, The Annals of thoracic surgery.

[18]  S. Shankaran,et al.  Adenosine infusion improves oxygenation in term infants with respiratory failure. , 1996, Pediatrics.

[19]  M. Berner,et al.  Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. , 1996, The American journal of cardiology.

[20]  R. McIntyre,et al.  Adenosine is a selective pulmonary vasodilator in cardiac surgical patients. , 1996, Chest.

[21]  S. Rich,et al.  Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. , 1995, Chest.

[22]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[23]  S. Rich,et al.  Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. , 1992, Journal of the American College of Cardiology.

[24]  T. Higenbottam,et al.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.

[25]  T. Evans,et al.  Adenosine as a Vasodilator in Primary Pulmonary Hypertension , 1991, Circulation.

[26]  J. Haller,et al.  Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. , 1989, Journal of Surgical Research.

[27]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[28]  J. Haller,et al.  Adenosine triphosphate: a potential therapy for hypoxic pulmonary hypertension. , 1988, Journal of pediatric surgery.